Proteins > Type-1 angiotensin II receptor
Page last updated: 2024-08-07 16:26:01
Type-1 angiotensin II receptor
An angiotensin II receptor 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P30556]
Synonyms
AT1AR;
AT1BR;
Angiotensin II type-1 receptor;
AT1
Research
Bioassay Publications (58)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.90) | 18.2507 |
| 2000's | 16 (27.59) | 29.6817 |
| 2010's | 32 (55.17) | 24.3611 |
| 2020's | 6 (10.34) | 2.80 |
Compounds (43)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| candesartan | Homo sapiens (human) | Affinity | 0.0001 | 1 | 1 |
| avapro | Homo sapiens (human) | Affinity | 0.0013 | 1 | 1 |
| losartan | Homo sapiens (human) | Affinity | 0.0064 | 1 | 1 |
| losartan | Homo sapiens (human) | Kb | 0.0060 | 3 | 3 |
| valsartan | Homo sapiens (human) | Affinity | 0.0017 | 1 | 1 |
| tasosartan | Homo sapiens (human) | Affinity | 0.0012 | 1 | 1 |
| telmisartan | Homo sapiens (human) | Affinity | 0.0010 | 1 | 1 |
| exp3174 | Homo sapiens (human) | Affinity | 0.0013 | 1 | 1 |
| exp7711 | Homo sapiens (human) | Affinity | 0.2300 | 1 | 1 |
| l 158809 | Homo sapiens (human) | Affinity | 0.0005 | 1 | 1 |
| eprosartan | Homo sapiens (human) | Affinity | 0.0092 | 1 | 1 |
Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on celEuropean journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.Journal of medicinal chemistry, , Mar-10, Volume: 59, Issue:5, 2016
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening.ACS medicinal chemistry letters, , Aug-12, Volume: 12, Issue:8, 2021
Chemokine receptor antagonists.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Designed multiple ligands. An emerging drug discovery paradigm.Journal of medicinal chemistry, , Oct-20, Volume: 48, Issue:21, 2005
Comparison of 3D structures and AT(1) binding properties of pyrazolidine-3,5-diones and tetrahydropyridazine-3,6-diones with parent antihypertensive drug irbesartan.Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002
Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.Journal of medicinal chemistry, , Aug-29, Volume: 45, Issue:18, 2002
Synthesis and pharmacological evaluation of new pyrazolidine-3, 5-diones as AT(1) angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group.Journal of medicinal chemistry, , 10-24, Volume: 62, Issue:20, 2019
[no title available]ACS medicinal chemistry letters, , Jan-10, Volume: 10, Issue:1, 2019
Exploring new scaffolds for angiotensin II receptor antagonism.Bioorganic & medicinal chemistry, , 09-15, Volume: 24, Issue:18, 2016
Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.Journal of medicinal chemistry, , Mar-10, Volume: 59, Issue:5, 2016
Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.European journal of medicinal chemistry, , Oct-20, Volume: 103, 2015
Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.European journal of medicinal chemistry, , Volume: 69, 2013
Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers.European journal of medicinal chemistry, , Volume: 62, 2013
The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.European journal of medicinal chemistry, , Volume: 55, 2012
Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.Bioorganic & medicinal chemistry, , Jul-15, Volume: 20, Issue:14, 2012
Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.European journal of medicinal chemistry, , Volume: 49, 2012
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010
New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.Journal of medicinal chemistry, , Apr-20, Volume: 49, Issue:8, 2006
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Recognition of privileged structures by G-protein coupled receptors.Journal of medicinal chemistry, , Feb-12, Volume: 47, Issue:4, 2004
NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.Journal of medicinal chemistry, , Nov-04, Volume: 47, Issue:23, 2004
Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.Journal of medicinal chemistry, , Sep-15, Volume: 38, Issue:19, 1995
Selective Discovery of GPCR Ligands within DNA-Encoded Chemical Libraries Derived from Natural Products: A Case Study on Antagonists of Angiotensin II Type I Receptor.Journal of medicinal chemistry, , 04-08, Volume: 64, Issue:7, 2021
Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on celEuropean journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003
[no title available],
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003
Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects.Bioorganic & medicinal chemistry letters, , Aug-05, Volume: 12, Issue:15, 2002
Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome.European journal of medicinal chemistry, , Jul-01, Volume: 173, 2019
Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 24, Issue:4, 2014
Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.European journal of medicinal chemistry, , Volume: 69, 2013
Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 23, Issue:3, 2013
Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.Bioorganic & medicinal chemistry, , Jul-15, Volume: 20, Issue:14, 2012
Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.European journal of medicinal chemistry, , Volume: 49, 2012
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.Journal of medicinal chemistry, , Jun-23, Volume: 54, Issue:12, 2011
Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 20, Issue:4, 2010
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group.Journal of medicinal chemistry, , 10-24, Volume: 62, Issue:20, 2019
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues.Journal of medicinal chemistry, , Sep-24, Volume: 52, Issue:18, 2009
Beta-homo-amino acid scan of angiotensin IV.Journal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008
Using conformational constraints at position 6 of Angiotensin II to generate compounds with enhanced AT2R selectivity and proteolytic stability.Bioorganic & medicinal chemistry letters, , 07-01, Volume: 43, 2021
Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.Journal of medicinal chemistry, , Mar-10, Volume: 59, Issue:5, 2016
The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1.Journal of medicinal chemistry, , Mar-11, Volume: 53, Issue:5, 2010
Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.Journal of medicinal chemistry, , Jul-05, Volume: 39, Issue:14, 1996
[no title available],
Synopsis of some recent tactical application of bioisosteres in drug design.Journal of medicinal chemistry, , Apr-28, Volume: 54, Issue:8, 2011
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.Journal of medicinal chemistry, , Jun-23, Volume: 54, Issue:12, 2011
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHBioorganic & medicinal chemistry, , 01-15, Volume: 25, Issue:2, 2017
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.Bioorganic & medicinal chemistry, , Apr-15, Volume: 24, Issue:8, 2016
Saralasin and Sarile Are AT2 Receptor Agonists.ACS medicinal chemistry letters, , Oct-09, Volume: 5, Issue:10, 2014
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.Bioorganic & medicinal chemistry, , May-15, Volume: 21, Issue:10, 2013
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.European journal of medicinal chemistry, , Volume: 63, 2013
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: deBioorganic & medicinal chemistry, , Nov-01, Volume: 18, Issue:21, 2010
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.Journal of medicinal chemistry, , Nov-27, Volume: 51, Issue:22, 2008
[no title available],
[no title available]Bioorganic & medicinal chemistry, , 07-01, Volume: 65, 2022
[no title available]Bioorganic & medicinal chemistry, , 07-15, Volume: 66, 2022
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996
Chemokine receptor antagonists.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.Journal of medicinal chemistry, , Aug-29, Volume: 45, Issue:18, 2002
Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.Bioorganic & medicinal chemistry, , Aug-01, Volume: 20, Issue:15, 2012
Designed multiple ligands. An emerging drug discovery paradigm.Journal of medicinal chemistry, , Oct-20, Volume: 48, Issue:21, 2005
Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.Journal of medicinal chemistry, , Aug-29, Volume: 45, Issue:18, 2002
Enables
This protein enables 5 target(s):
| Target | Category | Definition |
|---|
| angiotensin type I receptor activity | molecular function | An angiotensin receptor activity that acts via Gq-mediated activation of phospholipase C followed by phosphoinositide hydrolysis and Ca2+ signaling, and may act via additional signaling mechanisms. [GOC:mah, PMID:10977869] |
| angiotensin type II receptor activity | molecular function | An angiotensin receptor activity that acts via Gi protein coupling and cGMP (NO) generation, and may also act via additional signaling mechanisms. [GOC:mah, PMID:10977869] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| bradykinin receptor binding | molecular function | Binding to a bradykinin receptor. [GOC:mah, GOC:nln] |
| protein heterodimerization activity | molecular function | Binding to a nonidentical protein to form a heterodimer. [GOC:ai] |
Located In
This protein is located in 2 target(s):
| Target | Category | Definition |
|---|
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Involved In
This protein is involved in 28 target(s):
| Target | Category | Definition |
|---|
| regulation of cell growth | biological process | Any process that modulates the frequency, rate, extent or direction of cell growth. [GOC:go_curators] |
| kidney development | biological process | The process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and/or excretes the end products of body metabolism in the form of urine. [GOC:dph, GOC:mtg_kidney_jan10, ISBN:0124020607, ISBN:0721662544] |
| renin-angiotensin regulation of aldosterone production | biological process | The process in which an increase in active angiotensin stimulates the adrenal cortices to secrete aldosterone. [ISBN:0721643949] |
| maintenance of blood vessel diameter homeostasis by renin-angiotensin | biological process | The process in which the diameter of a blood vessel is changed due to activity of the renin-angiotensin system. [GOC:dph, GOC:pr, GOC:tb] |
| regulation of systemic arterial blood pressure by renin-angiotensin | biological process | The process in which renin-angiotensin modulates the force with which blood passes through the circulatory system. [GOC:mtg_cardio] |
| G protein-coupled receptor signaling pathway | biological process | The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. [GOC:bf, GOC:mah, PMID:16902576, PMID:24568158, Wikipedia:G_protein-coupled_receptor] |
| phospholipase C-activating G protein-coupled receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase C (PLC) and a subsequent increase in the intracellular concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG). [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194] |
| positive regulation of cytosolic calcium ion concentration | biological process | Any process that increases the concentration of calcium ions in the cytosol. [GOC:ai] |
| Rho protein signal transduction | biological process | An intracellular signaling cassette in which a small monomeric GTPase of the Rho subfamily relays a signal. [GOC:bf] |
| positive regulation of macrophage derived foam cell differentiation | biological process | Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. [GOC:add, GOC:dph, GOC:tb] |
| regulation of vasoconstriction | biological process | Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels. [GOC:jl] |
| calcium-mediated signaling | biological process | Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions. [GOC:signaling] |
| positive regulation of phospholipase A2 activity | biological process | Any process that activates or increases the activity of the enzyme phospholipase A2. [GOC:mah] |
| low-density lipoprotein particle remodeling | biological process | The acquisition, loss or modification of a protein or lipid within a low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase, with the subsequent loss of free fatty acid, and the transfer of cholesterol esters from LDL to a triglyceride-rich lipoprotein particle by cholesteryl ester transfer protein (CETP), with the simultaneous transfer of triglyceride to LDL. [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl] |
| regulation of renal sodium excretion | biological process | Any process that modulates the amount of sodium excreted in urine over a unit of time. [GOC:mtg_25march11, GOC:yaf] |
| angiotensin-activated signaling pathway | biological process | A G protein-coupled receptor signaling pathway initiated by angiotensin II binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nhn, GOC:signaling, PMID:10977869] |
| regulation of cell population proliferation | biological process | Any process that modulates the frequency, rate or extent of cell proliferation. [GOC:jl] |
| symbiont entry into host cell | biological process | The process by which a symbiont breaches the plasma membrane or cell envelope and enters the host cell. The process ends when the symbiont or its genome is released into the host cell. [GOC:jl] |
| regulation of inflammatory response | biological process | Any process that modulates the frequency, rate or extent of the inflammatory response, the immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. [GOC:ai] |
| positive regulation of inflammatory response | biological process | Any process that activates or increases the frequency, rate or extent of the inflammatory response. [GOC:ai] |
| positive regulation of protein metabolic process | biological process | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving a protein. [GOC:ai] |
| cell chemotaxis | biological process | The directed movement of a motile cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis). [GOC:dph] |
| phospholipase C-activating angiotensin-activated signaling pathway | biological process | A phospholipase C-activating G protein-coupled receptor signaling pathway initiated by angiotensin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:bf, GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
| blood vessel diameter maintenance | biological process | Any process that modulates the diameter of blood vessels. [GOC:pr] |
| positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis | biological process | Any process that activates or increases the frequency, rate or extent of blood vessel endothelial cell proliferation involved in sprouting angiogenesis. [GO_REF:0000058, GOC:TermGenie, PMID:23388056] |
| positive regulation of CoA-transferase activity | biological process | Any process that activates or increases the frequency, rate or extent of CoA-transferase activity. [GO_REF:0000059, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:20164328] |
| positive regulation of reactive oxygen species metabolic process | biological process | Any process that activates or increases the frequency, rate or extent of reactive oxygen species metabolic process. [GOC:mah] |
| inflammatory response | biological process | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732] |